Culture Biosciences

Culture Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $98.5M

Overview

Culture Biosciences is a private technology and services company founded in 2016 and headquartered in South San Francisco, California. It operates at the intersection of bioprocessing and digital technology, offering a suite of cloud-connected bioreactors and software designed to streamline and accelerate bioprocess development for biologics. The company's model is primarily service and platform-based, providing tools and lab services to biopharma companies, thereby generating early revenue. Its collaboration with industry leader Cytiva highlights its strategic positioning to modernize biomanufacturing workflows.

AI / Machine LearningBiologics

Technology Platform

Integrated platform of cloud-connected single-use bioreactors (Stratyx), cloud-native experiment management & analytics software (Console), and bioprocessing development services (Nexxys). Designed to generate structured data for AI/ML-driven bioprocess optimization.

Funding History

3
Total raised:$98.5M
Series B$80M
Series A$15M
Seed$3.5M

Opportunities

The rapid growth of complex biologics and cell/gene therapies creates high demand for efficient, data-driven process development.
The industry-wide shift towards digitalization (Industry 4.0) and AI in biomanufacturing positions Culture's cloud-data platform as a critical enabling technology.
Strategic partnerships with major players like Cytiva can dramatically accelerate market penetration and platform adoption.

Risk Factors

Slow adoption in a traditionally conservative biopharma manufacturing sector due to concerns over data security, IP, and changing established workflows.
Intense competition from large, established bioreactor companies expanding their digital offerings and from other service CROs.
Dependency on continued biotech sector funding for client R&D budgets.

Competitive Landscape

Culture competes with established bioreactor and bioprocess equipment vendors (e.g., Sartorius, Thermo Fisher Scientific, Cytiva itself) who are integrating software into their hardware. It also competes with contract development and manufacturing organizations (CDMOs) offering process development services and with emerging digital bioprocessing software startups. Its key differentiation is the tight, native integration of its own hardware, software, and services into a single data-generating platform.